Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today told DirectorsTalk that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Motif Bio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am ET on March 9.
The webcast will explore some of the technologies and companies tackling the emerging antibiotic resistance crisis. Participants will learn about established approaches to combat antibiotic resistance – including antibiotic-resistance breakers, macrocycles and other antibiotic classes for infections caused by key pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.
The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this vital topic.
Dr. David Huang is an infectious diseases specialist with over 15 years of clinical, academic, industry, and research experience in medicine and in infectious diseases. He is passionate about developing new antibacterials and antivirals especially for diseases caused by multidrug resistant organisms. Other webcast participants include:
· Dr. Marc Lemonnier, Co-founder and CEO of Antabio
· Dr. Prabhavathi Fernandes, Founder, President and CEO of Cempra Inc.
· Professor Anthony R.M. Coates, Chief Scientific Officer of Helperby Therapeutics
· Dr. Glenn Dale, Head of Early Development, Antimicrobials of Polyphor
· Moderator: Raveena Bhambra, Editor ofBioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.
